专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5472022A Injection pen solution transfer apparatus and method 失效
标题翻译：注射笔溶液转移装置及方法
公开(公告)号：US5472022A
公开(公告)日：1995-12-05
申请号：US146313
申请日：1993-11-02
申请人： Peter Michel , Robert S. Freeman , James Q. Oeswein
发明人： Peter Michel , Robert S. Freeman , James Q. Oeswein
IPC分类号： A61J1/00 , A61J1/20 , A61M5/24 , B65B1/04 , B65B3/04
CPC分类号： A61J1/2096 , A61M5/24 , A61J1/062 , A61J1/201 , A61J1/2013 , A61J1/2055 , A61M2005/2407 , A61M2005/2488 , A61M5/31515
摘要： An injection pen apparatus (30) for medicament injection including a medicament cartridge assembly (31) formed to receive and contain a medicament therein. A holding sleeve (34) is provided which is dimensioned to receive the medicament cartridge assembly (31) therein which mates with a solution transfer device (35) including an axially movable displacement rod (36). The injection pen apparatus (30) further includes a coupling mechanism (37) removably coupling the solution transfer device (35) to both a plunger (32) slidably movable in the cartridge (33) and to the holding sleeve (34). A sleeve mounting assembly (40) of the coupling mechanism (37) removably mounts the coupling mechanism to the holding sleeve (34). A locking device (41) is included which is formed and dimensioned to require joining of the displacement rod (36) relative the sleeve mounting assembly (40) after uncoupling of the rod from the plunger (32) and before uncoupling of a remainder of the solution transfer device (35) from the holding sleeve (34).
摘要翻译：一种用于药物注射的注射笔装置（30），包括形成为在其中容纳和容纳药物的药剂盒组件（31）。设有保持套筒（34），其尺寸适于容纳其中与包括可轴向移动的移动杆（36）的溶液转移装置（35）配合的药剂盒组件（31）。注射笔装置（30）还包括将溶液转移装置（35）可拆卸地连接到在盒（33）中可滑动地移动的柱塞（32）和保持套筒（34）的联接机构（37）。联接机构（37）的套筒安装组件（40）将联接机构可拆卸地安装到保持套筒（34）上。包括锁定装置（41），该锁定装置（41）形成并确定尺寸，以在杆与柱塞（32）脱离之后并且在将剩余部分（36）解耦之前需要相对于套筒安装组件（40）溶液转移装置（35）。

2. 发明申请

US20110230408A1 HUMAN GROWTH HORMONE AQUEOUS FORMULATION 审中-公开
标题翻译：人类生长激素水质配方
公开(公告)号：US20110230408A1
公开(公告)日：2011-09-22
申请号：US13150911
申请日：2011-06-01
申请人： Barbara H. O'Connor , James Q. Oeswein
发明人： Barbara H. O'Connor , James Q. Oeswein
IPC分类号： A61K38/27 , A61P43/00
CPC分类号： A61K38/27 , A61K9/0019 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26
摘要： A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.
摘要翻译：公开了含有人生长激素，缓冲液，非离子表面活性剂和任选的中性盐，甘露糖醇或防腐剂的稳定的药学上可接受的水性制剂。还公开了用于制备，储存和使用这些制剂的相关手段和方法。

3. 发明授权

US5783556A Formulated insulin-containing composition 失效
标题翻译：配制含胰岛素的组合物
公开(公告)号：US5783556A
公开(公告)日：1998-07-21
申请号：US696314
申请日：1996-08-13
申请人： Ross G. Clark , James Q. Oeswein , Douglas A. Yeung
发明人： Ross G. Clark , James Q. Oeswein , Douglas A. Yeung
IPC分类号： A61K45/00 , A61K9/00 , A61K38/27 , A61K38/28 , A61K38/30 , A61K47/02 , A61K47/10 , A61K47/12 , A61P3/10 , A61K38/00 , A61K38/24
CPC分类号： A61K9/0019 , A61K38/30 , A61K47/12 , A61K47/02 , A61K47/10
摘要： Formulations containing NPH insulin are useful for treating hyperglycemic disorders, such as diabetes, in a mammal in need of treatment. One such formulation, which is preferably administered parenterally, more preferably by injection, comprises IGF-I and NPH insulin, in amounts of from or about 1 to 10 mg IGF-I and from or about 0.2 to 2 mg NPH insulin in a pharmaceutically acceptable carrier. Another such formulation comprises IGF-I and NPH insulin in an acetic acid salt buffer. Still another formulation comprises IGF-I and NPH insulin in a weight ratio of NPH insulin to IGF-I of from or about 10:1 to 1:50 (w/w), from or about 0.05 to 0.3M of an osmolyte, from or about 0.1 to 10 mg/mL of a stabilizer, and from or about 5 to 100 mM of a buffer at from or about pH 5 to 7. A still further composition comprises NPH insulin in an acetic acid salt buffer.
摘要翻译：含有NPH胰岛素的制剂可用于治疗需要治疗的哺乳动物中的高血糖病症，例如糖尿病。一种这样的制剂，其优选通过胃肠外，更优选通过注射施用，包含IGF-1和NPH胰岛素，其量为约1-10mg IGF-I和约0.2至2mg NPH胰岛素，其药学上可接受的载体另一种这样的制剂在乙酸盐缓冲液中包含IGF-1和NPH胰岛素。另一制剂包含IGF-I和NPH胰岛素，NPH胰岛素与IGF-I的重量比为约10:1至1:50（w / w），或约0.05至0.3M的渗透液，来自或约0.1至10mg / mL的稳定剂，以及约或约5至100mM的缓冲液，其pH值至约为5至7.还有一种组合物包含在乙酸盐缓冲液中的NPH胰岛素。

4. 发明授权

US5374620A Growth-promoting composition and its use 失效
标题翻译：配方生长促进组合物及其用途
公开(公告)号：US5374620A
公开(公告)日：1994-12-20
申请号：US71818
申请日：1993-06-04
申请人： Ross G. Clark , Michael J. Cronin , Douglas A. Yeung , James Q. Oeswein
发明人： Ross G. Clark , Michael J. Cronin , Douglas A. Yeung , James Q. Oeswein
IPC分类号： A61K9/00 , A61K38/20 , A61K38/30 , A61K47/10 , A61K47/12 , A61K47/26 , A61K37/02 , A61K37/36
CPC分类号： A61K9/0019 , A61K38/27 , A61K38/30 , A61K47/10 , A61K47/12 , A61K47/26 , Y10S930/12
摘要： A combined formulation for IGF-I and growth hormone (GH) is useful for enhancing growth of a mammal. This formulation, which may be administered by infusion or injection to enhance growth, comprises IGF-I and GH, each in amounts of 0.1 to 100 mg/ml, in a pharmaceutically acceptable carrier at a pH of about 5-6 containing a surfactant, wherein the amounts of IGF-I and GH in the composition are effective to promote growth of a mammal more than an equivalent dose of IGF-I or GH alone, and wherein the weight ratio of IGF-I to GH in the composition ranges from 0.002:1 to 240:1.
摘要翻译： IGF-I和生长激素（GH）的组合制剂可用于增强哺乳动物的生长。可以通过输注或注射来施用以增强生长的该制剂在含有表面活性剂的pH约5-6的药学上可接受的载体中包含0.1至100mg / ml的IGF-1和GH，其中所述组合物中IGF-1和GH的量对于促进哺乳动物的生长有效地超过单独的IGF-1或GH等效剂量，并且其中组合物中IGF-1与GH的重量比为0.002 ：1〜240：1。

5. 发明授权

US5096885A Human growth hormone formulation 失效
标题翻译：人类生长激素配方
公开(公告)号：US5096885A
公开(公告)日：1992-03-17
申请号：US182262
申请日：1988-04-15
申请人： Rodney Pearlman , James Q. Oeswein
发明人： Rodney Pearlman , James Q. Oeswein
IPC分类号： A61K9/08 , A61K9/00 , A61K9/12 , A61K38/27 , A61K47/10 , A61K47/18 , A61K47/26
CPC分类号： A61K9/0019 , A61K38/27 , A61K47/10 , A61K47/183 , A61K47/26 , Y10S514/97 , Y10S514/975
摘要： A stable pharmaceutically acceptable formulation containing human growth hormone, glycine, mannitol, a buffer, and optionally, a non-ionic surfactant is disclosed. The formulation contains human growth-hormone: glycine in 1:50-200 molar ratios. Also disclosed are associated means and methods for preparing and using such formulations.
摘要翻译：公开了含有人生长激素，甘氨酸，甘露糖醇，缓冲剂和任选的非离子表面活性剂的稳定的药学上可接受的制剂。该制剂含有1:50-200摩尔比的人生长激素：甘氨酸。还公开了用于制备和使用这些制剂的相关手段和方法。

6. 发明申请

US20090163419A1 Human growth hormone aqueous formulation 审中-公开
标题翻译：人生长激素含水制剂
公开(公告)号：US20090163419A1
公开(公告)日：2009-06-25
申请号：US12321084
申请日：2009-01-15
申请人： Barbara H. O'Connor , James Q. Oeswein
发明人： Barbara H. O'Connor , James Q. Oeswein
IPC分类号： A61K38/22
CPC分类号： A61K38/27 , A61K9/0019 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26
摘要： A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.
摘要翻译：公开了含有人生长激素，缓冲液，非离子表面活性剂和任选的中性盐，甘露糖醇或防腐剂的稳定的药学上可接受的水性制剂。还公开了用于制备，储存和使用这些制剂的相关手段和方法。

7. 发明授权

US07186686B2 Formulated composition 有权
标题翻译：配方组成
公开(公告)号：US07186686B2
公开(公告)日：2007-03-06
申请号：US10431175
申请日：2003-05-06
申请人： James Q. Oeswein , John R. Smikahl , Sharon X. Wang , Douglas A. Yeung
发明人： James Q. Oeswein , John R. Smikahl , Sharon X. Wang , Douglas A. Yeung
IPC分类号： A61K38/28 , C07K17/00
CPC分类号： A61K9/0019 , A61K47/183 , A61K47/20 , A61K47/40 , Y10S435/808 , Y10S514/866 , Y10S530/808
摘要： A composition is disclosed that comprises a mixture of polypeptides of opposite charge and an excipient selected from the group consisting of arginine, lysine, glutamic acid, sodium dodecyl sulfate, beta-hydroxy cyclodextrin, and beta-cyclodextrin sulfobutyl ether.
摘要翻译：公开了包含相反电荷的多肽和选自精氨酸，赖氨酸，谷氨酸，十二烷基硫酸钠，β-羟基环糊精和β-环糊精磺丁基醚的赋形剂的混合物的组合物。

8. 发明授权

US06559122B1 Formulated composition 有权
标题翻译：配方组成
公开(公告)号：US06559122B1
公开(公告)日：2003-05-06
申请号：US09539310
申请日：2000-03-30
申请人： James Q. Oeswein , John R. Smikahl , Sharon X. Wang , Douglas A. Yeung
发明人： James Q. Oeswein , John R. Smikahl , Sharon X. Wang , Douglas A. Yeung
IPC分类号： A61K3828
CPC分类号： A61K9/0019 , A61K47/183 , A61K47/20 , A61K47/40 , Y10S435/808 , Y10S514/866 , Y10S530/808
摘要： A composition is disclosed that comprises a mixture of polypeptides of opposite charge and an excipient selected from the group consisting of arginine, lysine, glutamic acid, sodium dodecyl sulfate, beta-hydroxy cyclodextrin, and beta-cyclodextrin sulfobutyl ether.
摘要翻译：公开了包含相反电荷的多肽和选自精氨酸，赖氨酸，谷氨酸，十二烷基硫酸钠，β-羟基环糊精和β-环糊精磺丁基醚的赋形剂的混合物的组合物。

9. 发明授权

US5597802A Method of formulating IGF-I with growth hormone 失效
标题翻译：用生长激素配制IGF-I的方法
公开(公告)号：US5597802A
公开(公告)日：1997-01-28
申请号：US458595
申请日：1995-06-02
申请人： Ross G. Clark , Douglas A. Yeung , James Q. Oeswein
发明人： Ross G. Clark , Douglas A. Yeung , James Q. Oeswein
IPC分类号： A61K9/00 , A61K38/00 , A61K38/20 , A61K38/30 , A61K47/10 , A61K47/12 , A61K47/26 , C07K14/47 , C07K14/65 , G01N33/68 , A61K38/27
CPC分类号： A61K38/27 , A61K38/30 , A61K47/10 , A61K9/0019 , C07K14/4702 , G01N33/6872 , A61K47/12 , A61K47/26
摘要： A formulation for IGF-I is disclosed that is useful in treating hyperglycemic disorders and, in combination with growth hormone, in enhancing growth of a mammal. Also disclosed is a process for preparing a formulation of growth hormone and IGF-I from the IGF-I formulation. The IGF-I formulation comprises about 2-20 mg/ml of IGF-I, about 2-50 mg/ml of an osmolyte, about 1-15 mg/ml of a stabilizer, and a buffered solution at about pH 5-5.5, optionally with a surfactant.
摘要翻译：公开了用于治疗高血糖病症和与生长激素联合用于增强哺乳动物生长的IGF-1的制剂。还公开了从IGF-I制剂制备生长激素和IGF-I的制剂的方法。 IGF-I制剂包含约2-20mg / ml的IGF-I，约2-50mg / ml的渗透液，约1-15mg / ml的稳定剂和约pH5.5.5的缓冲溶液，任选地与表面活性剂。

10. 发明授权

US06991790B1 Antibody formulation 有权
标题翻译：抗体配方
公开(公告)号：US06991790B1
公开(公告)日：2006-01-31
申请号：US09724868
申请日：2000-11-28
申请人： Xanthe M. Lam , James Q. Oeswein , Boonsri Ongpipattanakul , Zehra Shahrokh , Sharon X. Wang , Robert P. Weissburg , Rita L. Wong
发明人： Xanthe M. Lam , James Q. Oeswein , Boonsri Ongpipattanakul , Zehra Shahrokh , Sharon X. Wang , Robert P. Weissburg , Rita L. Wong
IPC分类号： A61K39/395 , C07K16/00 , C07K16/28
CPC分类号： C07K16/2896 , A61K39/39591 , C07K16/2845 , C07K2317/54
摘要： A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of antibody not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.0, a surfactant and a polyol is described, along with uses for such a formulation.
摘要翻译：描述了一种稳定的含水药物制剂，其包含治疗有效量的未经预先冻干的抗体，将pH保持在约4.5至约6.0范围内的缓冲液，表面活性剂和多元醇，以及用于该制剂的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式